期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胱抑素C在造影剂肾病早期诊断中的价值 被引量：7

暂未订购
导出
摘要 [目的]探讨胱抑素C（Cys C）在造影剂肾病（CIN）早期诊断中的价值.[方法]对105例接受碘海醇造影的患者分别测定不同时段血肌酐、血Cys C水平,采用ROC曲线评价血清Cys C的诊断价值.[结果]本组共105例病人符合观察标准,其中12例病人诊断为CIN,发病率为11.4%,CIN组患者和非CIN组患者,术前血Cys C浓度在两组病人中无明显差异,术后CIN组患者,Cys C浓度持续性升高,并显著高于非CIN组.术后12 h血Cys C浓度的ROC曲线显示Cys C浓度为1.16 mg/L时候具有最大曲线下面积,此时对应的特异性是73%,敏感性是85%.[结论]接受造影剂治疗的患者,血Cys C浓度可作为造影剂相关肾损害的内源性标志物,对CIN的早期诊断有重要作用.
作者 邹琴 廖湘平 郭胜根
机构地区 郴州市第一人民医院肾内科郴州市肾脏病研发中心
出处 《医学临床研究》 CAS 2011年第12期2379-2381,共3页 Journal of Clinical Research
关键词 肾疾病/诊断 造影剂 半胱氨酸蛋白酶抑制剂
分类号 R692 [医药卫生—泌尿科学]
  • 相关文献

参考文献9

二级参考文献34

  • 1Molitoris B A, Levin A, Warnock D G, et al. Improving outcomes of acute kidney injury: report of an initiative[J]. Nat Clin Pract Nephrol,2007,3(8):439-442.
  • 2Bagshaw S M, George C, Bellomo R. Changes in the incidence and outcome for early acute injury in a cohort of Australian intensive care units[J]. Crit Care,2007,11(3):3-11.
  • 3Cruz D N, Goh C Y, Haase-Fielitz A, et al. Early biomarkers of renalinjury[J]. Conqest Heart Fail,2010,16(7):S25-31.
  • 4Peralta C A, Katz R, Sarnak M J. Cystatin C identifies chronic kidney disease patients at higher risk for complications[J]. J Am Soc Nephro1,2011,22(1) :147-155.
  • 5Finney H, Newman D J, Thakkar H, et al. Reference ranges for plasma cystatin C and ereatinine measurements in premature infants, neonates, and older children[J]. Arch Dis Child,2000, 82(1) :71-75.
  • 6Ferrannini M, Vischini G, Di Daniele N, et al. Cystatin C: a promising misunderstood biomarker for the diagnosis of acute kidneyinjury[J]. Kidney Int,2008,74(12):1008-1016.
  • 7Rovakkers A A, Korevaar J C, Van Suijlen J. Serum and cystatin are poor biomarkers for acute kidney injury and replacement therapy[J]. Intensive Care Med,2011,37(3):493-501.
  • 8Wasen E, Isoaho R, Mattila K, etal. Serum cystatin Cin the aged: relationships with health status[J]. Am J Kidney Dis, 2003,42(1) :36-43.
  • 9周玉红 左力 王梅.MDRD方程预测肾小球滤过率的临床应用评价[J].中华肾脏病杂志,2004,20:30-34.
  • 10Randers E, Erlandsen EJ. Serum Cystatin C as an endogenous marker of the renal function - a review. Clin Chem Lab Med , 1999,37:389-395.

共引文献194

同被引文献62

  • 1李萍,赵莹,余霆.肾脏滤过功能损伤实验室诊断指标半胱氨酸蛋白酶抑制剂C的系统评价[J].检验医学,2005,20(5):474-478. 被引量：10
  • 2冷敏,窦超.加强水化预防介入治疗并发造影剂肾病的护理[J].实用全科医学,2007,5(1):90-91. 被引量：26
  • 3孔岩,杨建梅,徐国宾,李淑葵,张春丽,郭晓蕙.对2型糖尿病患者肾小球滤过功能的评价[J].中华检验医学杂志,2007,30(11):1219-1222. 被引量：39
  • 4Yoon H J, Kim H, Lee JP, et al. The efficacy of the cysta- tin C based glomerular filtration rate in the estimation of safe contrast media volume[J]. Korean Circ J, 2013,43 (9) :622-627.
  • 5Duan SB,I.iu GL,Yu ZQ,et al. Urinary KIM-1 ,IL-18 and Cys-c as early predictive biomarkers in gadolinium-based contrast-induced nephropathy in the elderly patients[J]. Clin Nephrol,2013,80(5) :349-354.
  • 6Tanaga K, Tarao K, Nakamura Y, et al. Percutaneous cor- onary intervention causes increase of serum cystatin C concentration even in the patients with a low risk of con- trast-induced nephropathy[J]. Cardiovasc Interv Ther, 2012,27(3) : 168-173.
  • 7Cronin RE. Contrast-induced nephropathy:pathogenesis and prevention[J].Pediatric Nephrology,2010,(02):191.
  • 8Ishibashi Y,Yamauchi M,Musha H. Impact of contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal insufficiency patients undergoing cardiac catheterization[J].Angiology,2010,(08):724.
  • 9Sato H,Kazama JJ,Kuroda T. Serum cystatin C measured by a sol particle homogeneous immunoassay can accurately detect early impairment of renal function[J].Clinical and Experimental Nephrology,2008,(04):270.doi:10.1007/s10157-008-0047-4.
  • 10Gami AS,Garovic VD. Contrast nephropathy after coronary anography[J].Mayo Clinic Proceedings,2004,(02):211.

引证文献7

二级引证文献32

医学临床研究
2011年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部